Array BioPharma announced positive results from the Phase III BEACON CRC trial evaluating a triple combination of the BRAF inhibitor Braftovi (encorafenib), the MEK inhibitor Mektovia (binimetinib), and the anti-EGFR antibody Erbitux (cetuximab) in patients with advanced BRAFV600E-mutant metastatic colorectal cancer after one or two lines of therapy.

Shares of Exelixis fell after the company disclosed in a U.S. SEC filing that a Phase III melanoma trial failed to hit endpoints.